Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia

Purpose

RATIONALE: Immunotoxins, such as anti-CD19 and anti-CD22, can find cancer cells that express CD19 and CD22 and kill them without harming normal cells. This may be an effective treatment for B-cell acute lymphoblastic leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of anti-CD19 and anti-CD22 immunotoxins in treating patients with refractory or relapsed B-cell acute lymphoblastic leukemia.

Condition

  • Leukemia

Eligibility

Eligible Ages
Between 17 Years and 120 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed adult acute lymphoblastic leukemia

- B-cell lineage

- Refractory or relapsed disease based on a bone marrow/peripheral blood examination,
cytogenetic studies, or polymerase chain reaction amplification

- Disease refractory to conventional therapy and other therapies of higher priority

- At least 50% of the blasts (in bone marrow or peripheral blood) expressing CD19 and/or
CD22 by flow cytometry

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy > 2 months

- Creatinine < 1.5 times normal

- Bilirubin < 1.5 times normal

- ALT or AST < 2.5 times normal

PRIOR CONCURRENT THERAPY:

- Prior chemotherapy, biologic therapy, and/or radiotherapy allowed

Study Design

Phase
Phase 1
Study Type
Interventional
Primary Purpose
Treatment

Recruiting Locations

Albert Einstein Cancer Center at Albert Einstein College of Medicine
Bronx, New York 10461
Contact:
Clinical Trials Office - Albert Einstein Cancer Center at Albe
718-904-2730
aecc@aecom.yu.edu

More Details

NCT ID
NCT00450944
Status
Recruiting
Sponsor
Albert Einstein College of Medicine

Study Contact

Detailed Description

OBJECTIVES:

- Determine the maximum tolerated dose of deglycosylated ricin A chain-conjugated anti-CD19 and anti-CD22 immunotoxins (Combotox) in patients with refractory or relapsed B-cell acute lymphoblastic leukemia.

- Determine the toxicity of Combotox in these patients.

- Determine the pharmacokinetic (PK) profile of Combotox in these patients.

- Determine any antitumor activity of Combotox, in terms of the percentage of blasts in bone marrow and peripheral blood.

- Determine the levels of human antimouse and human anti-dgA antibodies in patients treated with Combotox.

- Determine if there is a correlation between PK parameters and toxicity of Combotox in these patients.

- Determine if the expression of the CD19 and CD22 cell surface antigens is affected by Combotox.

OUTLINE: This is a dose-escalation study.

Patients receive deglycosylated ricin A chain-conjugated anti-CD19 and anti-CD22 immunotoxins (Combotox) IV over 4 hours on days 1, 3, and 5 in the absence of disease progression or unacceptable toxicity.

Cohorts of patients receive escalating doses of Combotox until the maximum tolerated dose is determined.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.